Evidence map›Paper›PMID 39976856›Full record

ReviewMolecular biology reports2025

Rheumatoid arthritis unmasked: the power of B cell depletion therapy.

Tawfeeq Alghazali, Raed Obaid Saleh, Subasini Uthirapathy, Suhas Ballal, Shahabe Saquib Abullais, Rishiv Kalia, Renu Arya, Rsk Sharma, Abhinav Kumar, Resan Shakir Abdulamer

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tawfeeq AlghazaliThe Islamic University, Najaf, Iraq.ORCID https://orcid.org/0000-0003-0131-3992
Raed Obaid SalehDepartment of Medical Laboratory Techniques Department, College of Health and Medical Technology, University of Al Maarif, Al Anbar, 31001, Iraq. Dr.raed.obaid@uoa.edu.iq.ORCID http://orcid.org/0000-0003-3873-3181
Subasini UthirapathyPharmacy Department, Tishk International University, Erbil, Kurdistan Region, Iraq.
Suhas BallalDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Shahabe Saquib AbullaisDepartment of Periodontics and Community Dental Science, College of Dentistry, King Khalid University, Abha, Saudi Arabia.
Rishiv KaliaCentre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, India.ORCID https://orcid.org/0009-0006-7740-9666
Renu AryaDepartment of Pharmacy, Chandigarh Pharmacy College, Chandigarh Group of Colleges- Jhanjeri, Ajitgarh, Punjab, India.
Rsk SharmaDepartment of Chemistry, Raghu Engineering College, Visakhapatnam, India.ORCID https://orcid.org/0000-0001-9338-8208
Abhinav KumarRefrigeration and Air-condition Department, Technical Engineering College, The Islamic University, Najaf, Iraq.
Resan Shakir AbdulamerDepartment of Medical Laboratories Technology, Al-Nisour University College, Nisour Seq. Karkh, Baghdad, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is an enduring autoimmune illness characterized by persistent inflammation and joint damage. Recent advancements in B cell depletion therapies (BCDTs) have provided new avenues for managing RA. This review article delves into the pathophysiology of RA, highlighting the pivotal role of B cells in disease progression. We explore the mechanisms underlying B cell depletion, focusing on monoclonal antibodies such as rituximab as well as innovative approaches like chimeric antigen receptor (CAR) T cell therapies. An in-depth analysis of clinical studies reveals the efficacy and limitations of these therapies, including success rates, side effects, and cost implications for patients. Despite promising outcomes, the incomplete depletion of B cells and associated risks underscore the need for further research. This review aims to provide a comprehensive understanding of BCDTs in RA, shed light on their potential and challenges, and guide future therapeutic strategies.

Indexed as

Arthritis, RheumatoidB-LymphocytesLymphocyte DepletionAnimalsHumansImmunotherapy, AdoptiveRituximabRituximabAutoimmuneB cellImmune cellRheumatoid arthritis

Identifiers

PMID39976856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.